EN
Did Higher Earnings Per Share Just Shift GE HealthCare's (GEHC) Investment Narrative?
- GE HealthCare Technologies reported third quarter 2026 basic and diluted earnings per share from continuing operations of US$1.36, compared with US$0.98 a year earlier, and nine month basic EPS of US$3.45 and diluted EPS of US$3.44.
- The company paired this earnings update with ongoing investment in imaging platforms such as StarGuide GX and LOGIQ Focus. This signals continued spending on higher value equipment and digital tools even as profitability metrics from continuing operations moved higher.
- We will look at how GE HealthCare Technologies' higher third quarter earnings per share reshapes the broader investment narrative around the business.
GE HealthCare Technologies Investment Narrative Recap
To own GE HealthCare Technologies, you need to be comfortable that higher value imaging and digital tools can offset pressure in weaker areas like Patient Care Solutions. The latest third quarter EPS from continuing operations gives some support that the core operations are holding up. It does not remove the overhang from tariffs, investigations or the high debt load.
In the short term, the key swing factor is whether management can keep margin progress intact while working through supply chain issues and regulatory overhangs. The biggest risk is that tariff costs and PCS execution problems resurface at the same time, which could squeeze earnings despite contributions from imaging and Pharmaceutical Diagnostics.
The StarGuide GX clinical evaluation program looks most relevant to the recent earnings print because it sits directly inside GE HealthCare Technologies' imaging push. Multiple leading hospitals across the United States, Europe, China and Israel are assessing real world image quality, workflow and quantitative performance, which ties straight into how future systems could be specified and priced.
If StarGuide GX converts into broader adoption over time, it could support the view that new imaging platforms and AI enabled tools help mix earnings toward higher value equipment and software. Execution risk is still present. Management needs to translate these collaborations into orders, then ship and service them efficiently while keeping margin drag from tariffs and PCS issues in check.
GE HealthCare Technologies' current earnings are about US$2.2b, with analysts forecasting consensus earnings of US$2.8b by 2029 on projected revenues of US$25.0b. That outlook implies 4.9% yearly revenue growth and an earnings increase of roughly US$0.6b from earnings today.
Uncover why GE HealthCare Technologies' fair value indicates a 13% potential upside to its current price that could narrow quickly.
Exploring Other Perspectives
One alternate view on GE HealthCare Technologies leans hard into the backlog catalyst. The most optimistic analysts were already working off a record US$21.8b backlog and expecting revenue around US$25.6b and earnings of US$3.0b by 2029. You can treat the latest EPS and imaging updates as fresh information that might shift those expectations, in either direction.
Explore 3 other GE HealthCare Technologies fair value estimates, including one that suggests as much as 118% upside from the current price!
Decide For Yourself
Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so consider your own independent analysis.
- A great starting point for your GE HealthCare Technologies research is our analysis highlighting 3 key rewards and 1 important warning sign that could impact your investment decision.
- See our latest analysis for GE HealthCare Technologies. The report includes a comprehensive fundamental analysis summarized in a single visual, the Snowflake, making it easy to evaluate GE HealthCare Technologies' overall financial health at a glance.
Looking for more GE HealthCare Technologies style ideas?
If the GE HealthCare Technologies story has sharpened your thinking about where you want risk, income and balance sheet strength, it can help to line that up against a wider watchlist using the Simply Wall St Screener.
- For investors who want quality at a discount, start with a shortlist of 33 high quality undervalued stocks that combine fundamentals with pricing that may look appealing.
- If capital preservation sits high on your checklist, focus on resilience first by reviewing 29 resilient stocks with low risk scores that score well on our risk metrics.
- For those who care most about balance sheet strength, compare GE HealthCare Technologies with a list of solid balance sheet and fundamentals (24 results) to see which businesses are built to handle tougher conditions.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com